<DOC>
	<DOCNO>NCT01050517</DOCNO>
	<brief_summary>This randomise , control , double blind clinical study investigate safety efficacy combination albendazole , ivermectin praziquantel treatment child age 5-18 year co-infected lymphatic filariasis , schistosomiasis soil-transmitted helminthiasis .</brief_summary>
	<brief_title>Safety Efficacy Drug Combinations Against Triple Infections</brief_title>
	<detailed_description />
	<mesh_term>Parasitic Diseases</mesh_term>
	<mesh_term>Albendazole</mesh_term>
	<mesh_term>Praziquantel</mesh_term>
	<mesh_term>Ivermectin</mesh_term>
	<criteria>Those class one six time study Aged 518 year find infect either SCH , STH LF treatment group 1,2 3 infected SCH LF treatment group 4 infect three treatment group 5 Who willing consent whose parent consent , include study . Those acute chronic disease target infection history serious adverse drug reaction include study . Children total bilirubin &gt; 50Âµmol/L ALAT ( Alanine transferase ) &gt; 70IU/L qualify recruitment .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>